TIF Awards Contract to Biovista for the Installation of the JAnaemia Patient
Record Management System
CHARLOTTESVILLE, VA and
"We are very pleased that the TIF selected JAnaemia as its patient record management system amongst some very worthy competitors," said Andreas Persidis, Ph.D., CEO of Biovista. "We are confident that JAanemia will offer doctors and other medical and research staff of the hospitals a resource that will help them provide better care to patients and ultimately understand this challenging disease better", said Spyros Deftereos, MD, Ph.D., VP Drug Discovery.
"The TIF is glad to have selected JAnaemia as the system that will help medical staff at our two hospitals, collect, manage and analyze patient records in a systematic way that will hopefully lead to better care for beta-thalassaemia patients", said
About Biovista and the JAnaemia platform
Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista's technology platform allows the company's experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and auto-immune diseases. JAnaemia is the part of Biovista's platform that focuses on patient record management. It is a modular system that can include customer selected specific modules (such as Cardiology, and endocrinology) that optimize the system's performance for specific diseases of interest. JAnaemia has already been used in a research context for the determination of echocardiographic indices that predict clinical course in patients with beta-thalassemia.
For further information: For further information: Dr. Spyros Deftereos, VP DD, Biovista, +30-210-9629848, [email protected]; or Dr Androulla Eleftheriou, Executive Director, +357-22-319-129, [email protected]
Share this article